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Abstract 
The Coronavirus Disease 2019 (COVID-19) represents the
first medical catastrophe of the new millennium. Although imag-
ing is not a screening test for COVID-19, it plays a crucial role in
evaluation and follow-up of COVID-19 patients. In this paper, we
will review typical and atypical imaging findings of COVID-19.
Introduction
The Coronavirus Disease 2019 (COVID-19) represents the first
medical catastrophe of the new millennium. COVID-19 initially
presented in China, in the Wuhan area, Hubei province, at the end
of 2019, and quickly spreads around the globe because of its easy
human-to-human transmission, hospital infection, and international
air travel [1-4]. At the time of this writing, more than 34 million
confirmed cases, and more than one million of deaths were reported
globally by the World Health Organization (WHO) [5]. COVID-19
is due to an aggressive, highly contagious, betacoronavirus that
involves mainly the respiratory system. Fever, dry cough, and dys-
pnea are the most common symptoms, while rhinorrhea and sneez-
ing are less frequent [6]. This suggests that the target cells are pref-
erentially located in the lower airways [6]. Less frequently, patients
present central nervous system or gastrointestinal symptoms [6].
The absence of clinical symptoms was reported in approximately
50% of patients at the time of first diagnosis [7]. 
Individuals with old age, obesity, or other comorbidities are at
increased risk to develop pneumonia, acute respiratory distress syn-
drome, and multiorgan failure suggesting that COVID-19 patho-
genicity can depend on patient immune response [8,9]. Because of
the absence of proven drugs and vaccines, early diagnosis, timely
treatment, and immediate patient isolation are the pillars for con-
taining the infection. The gold standard for diagnosis is positive
results of real-time reverse transcription–polymerase chain reaction
(RT-PCR) test of swabs taken from the nasopharynx and/or orophar-
ynx [3,10]. However, a high rate of false-negative RT-PCR results
is reported due to multiple causes, such as insufficient cellular mate-
rial for detection and improper extraction of nucleic acids from clin-
ical materials [11,12]. This leads to a delay in diagnosis and treat-
ment, and a spread of the disease. Imaging can flag suspicious cases
and alert referring physicians. In this paper we review the role of
imaging in COVID-19 patients.
Chest findings
Chest CT is the main imaging methodology for detecting pul-
monary involvement and optimized the future treatment because
of high sensitivity and speed [13-15]. Although CT is not a screen-
ing test for COVID-19, it is strongly recommended for initial eval-
uation and follow-up of COVID-19 positive patients and to
exclude other disease conditions, which can be treated (e.g., pul-
monary embolism) [10,16,17]. Other imaging tests such as chest
radiography (CXR) and lung ultrasound (LUS) are not routinely
recommended in clinal practice.
CXR has low sensitivity for the detection of COVID-19 pneu-
monia in early and mild stages [8]. Currently, CXR is indicated in
severe and critical COVID-19 patients, which require bedside
exam, and in resource-constrained environments [18]. 
LUS has been proposed as an alternative tool to quickly assess
lung injury. LUS can identify alteration in subpleural regions,
which represents the typical COVID-19 locations [19]. Similar to
CXR, LUS has some utility in bedside in critical patients [20].
Almost all COVID-19 confirmed patients show typical CT fea-
tures including bilateral ground glass opacities (GGO), consolida-
tion, vascular enlargement, and crazy-paving pattern. Most abnor-
malities are bilateral and involve more segments with a predomi-
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nant peripheral and posterior distribution and a slight predomi-
nance of lower lobes [21,22]. During the course of disease nodule,
reversed halo sign, pleural changes, pericardial effusion, and
enlargement of hilar and mediastinal lymphadenopathies can also
occur. Infection control and regression of CT abnormalities can
lead to tissue organization and fibrosis [23,24]. Extra-pulmonary
abnormalities are absent in early stages and can occur in severe
type of disease [24]. Unfortunately, CT findings of COVID-19 are
not specific and overlap with those of other viral and not viral
pneumonia [22,25-27]. Moreover, CT features are not always con-
sistent with the clinical stage. Specifically, some asymptomatic
patients can show typical CT features and some patients with clin-
ically severe disease can show normal CT [28]. 
Ground glass opacity 
GGO represents the most common CT finding in COVID-19
patients, with a reported incidence of 49 to 94% [29]. GGO is an
area of increased attenuation with the preservation of bronchial
and vascular margins [30]. In the context of COVID-19, GGO
results from by partial filling of airspaces and interstitial thicken-
ing [30]. Three patterns of GGO have been described: pure GGO,
GGO with superimposed intra and interlobular septal thickening
(“crazy paving”), and GGO with consolidation [22] (Figure 1).
Different patterns can often be seen simultaneously in the same
patient [22]. Pure GGO and GGO with consolidation are the most
common patterns in early stage of the disease [23,24]. Of note,
GGO with peripheral distribution and unilateral location is the
most common abnormality in asymptomatic (so called covert
transmitter), patients.
Consolidation
Consolidation is a patchy area of increased attenuation, which
renders the lung solid (Figure 2) [30]. Unlike GGO, the filling of
airspaces is complete and obscures totally bronchial and vascular
margins [30], suggesting disease progression [22]. Air bron-
chograms within the consolidation can often be found.
Consolidation is reported in 11 to 73% of patients [21], and is seen
much more frequently in the elderly than in young patients [22]. Its
presence is rare in early-stage and typically occurs in progressive
and peak stages [23]. Multiple consolidations are the most com-
mon imaging features in the intensive care unit patients [31]. 
Crazy paving pattern
Crazy paving pattern is defined as a GGO with superim-
posed thickened intra- and inter-lobular septa (Figure 1C) [30].
The latter is due to lymphocyte infiltration of small interstitium
[32,33]. It occurs in 5% to 43% of patients [23,24]. Crazy
paving pattern is a common finding in progressive and peak
stage of the disease [23]. 
Vascular enlargement 
Vascular enlargement refers to a segmental or subsegmental
pulmonary artery with a diameter >3 mm in GGO and consolida-
tion areas (Figure 3). It is a common finding in COVID-19 patients
and was reported in 70 to 90% of patients [15, 35,36]. This finding
is probably related to three processes, in isolation or varying com-
binations: hyperemia induced by acute inflammatory reaction;
small pulmonary embolism, and COVID-19 induced vasculitis
[36]. Since this sign was not described in other pneumonia, it may
be useful to the identify COVID-19 [36]. 
Reversed halo sign
The reversed halo sign (also called atollo sign) refers to a
central round or half-moon shape GGO surrounded by a com-
plete or partial ring-like area of consolidation (Figure 4) [30].
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Figure 1. GGO patterns. A) Axial unenhanced CT image obtained in a 66-year-old male shows multiple bilateral patchy ground glass
opacities (circles) with predominantly peripheral distribution. B) Axial unenhanced CT image obtained in a 50-year-old female shows
ground glass opacities with consolidation in the lower left lung lobe and in the lingula. C) Axial CT image obtained in a 68-year-old
female shows a marked crazy paving in the left lower lung lobe.
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The pathological responsible mechanism is the inflammatory
reaction, which leads to alveolar septal thickening and cellular
debris in the alveoli [37]. This sign is extremely rare in COVID-
19 patients. Bernheim et al. reported its presence in approximate-
ly 2% in a series of 121 patients [34]. The detection of this sign
can suggest a progression from GGO to consolidation or an
inflammatory repair [34,38]. 
Nodule
A discrete nodule is a rounded opacity, measuring less than 3
cm in diameter (Figure 5A) [30]. A pure solid nodule is a rare find-
ing in COVID-19 patients. More frequently, a nodule is surround-
ed by a peripheral halo of GGO, due to diffuse progressive alveolar
damage (“halo sign”) (Figure 5B) [33,39,40]. The halo sign is typ-
ically described in early-stage of disease [15,33-40].
Fibrosis
Fibrosis is a dysregulated repair process to an inflammatory
reaction [41]. In case of COVID-19 pneumonia, alveolar epithelial
injury can activate fibroblasts and myofibroblasts to repair the
damage resulting in lung fibrosis and irreversible injury [32,41].
Fibrosis and strip-like lesions can cause bronchial traction and
consequent bronchus irreversible distortion (i.e., bronchiectasis)
(Figure 6) [42]. 
Subpleural curvilinear line
A subpleural curvilinear line is a curvilinear opacity, 1-3 mm
in thickness, parallel to the pleural surface (Figure 7). It may occur
for a supine position or may reflect edema or fibrosis process [30]. 
This finding is reported in approximately 10% of asympto-
matic patients and probably is due to edema or fibrosis [42,43].
When it is found in the dependent, posteroinferior portion of the
lung, atelectasis is the most likely cause [30]. 
Pleural changes
Pleural effusion and pleural thickening more frequently
occur in severe COVID-19 patients (Figure 8) [43,44]. In a large
meta-analysis, Zhu et al. have reported pleural thickening in
27.1% of patients and pleural effusion in 5.3% of patients [45].
Pleural inflammatory reaction can be due to inflammation
spread from subpleural lesions and septa [46]. Pleural effusion
can also be related to fluid overload due to prior cardiac or renal
disease [44]. 
Hilar and mediastinal lymphadenopathy
Hilar or mediastinal lymphadenopathy is a lymph node with a
short axis greater than 1 cm (Figure 9) [30]. It is a rare finding and
occurs in severe disease [35,43]. 
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Figure 2. Axial CT image obtained in a 50-year-old female
COVID-19 patient shows a subpleural consolidation area (circle)
in middle and lower lung lobes. 
Figure 3. Axial contrast-enhanced CT image obtained in a 33-
year-old female COVID-19 patient shows vascular enlargement
due to a thrombus (arrow) in a large consolidation area (asterisk).
Pericardial effusion
Pericardial effusion is rare and suggests a severe condition
(Figure 8) [35,43]. Of note, the concomitant presence of lym-
phadenopathies, pleural effusion, and extensive tiny lung nodules
raise suspicion of bacterial superinfection [47]. 
Abdominal findings
Abdominal manifestations, including gastrointestinal (GI)
symptoms (e.g., diarrhea and vomiting) and abnormal liver func-
tion are not uncommon and usually occur in severe stage of
COVID-19 [48]. Isolated abdominal manifestations at presentation
(i.e., without respiratory symptoms) are less frequent [48]. In a
meta-analysis including 6064 patients, Mao et al. have found GI
symptoms in 15% of patients, abnormal liver function in 19% of
patients, and isolated GI symptoms in 10% of patients [48]. The
latter has an increased risk of delayed diagnosis of COVID-19 with
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Figure 4. Axial CT image obtained in a 23-year-old female
COVID-19 patient shows a ground glass area surrounded by a
ring-like consolidation area (circle) in the peripheral right lower
lobe (reversed halo sign).
Figure 5. Lung nodule. A) Axial unenhanced CT image obtained in a 61-year-old female shows a nodule (circle) in the right upper lobe.
Also note pleural effusion (asterisk). B) Axial CT image obtained in a 61-year-old female COVID-19 patient shows a nodule surrounded
by a ground glass halo (arrow) in the peripheral right lower lobe (halo sign).
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the risk of virus-spreading [48]. In this case, the detection of typi-
cal findings of COVID-19 pneumonia on the lung bases of
abdomen CT scan, can raise the suspicion of COVID-19, despite
the absence of respiratory symptoms [49]. 
GI and liver involvement can be due to the expression of
angiotensin converting enzyme 2 (ACE2), the major receptor of
coronavirus or microvascular injury due to inflammation response,
that leads to arterial and venous thrombi [50-52]. 
GI abnormalities are preferentially evaluated at CT and include
bowel wall thickening, pneumatosis, portal venous gas, thrombosis
of the portal vein (Figure 10) and upper mesenteric vessels and
bowel ischemia [50,53,54]. 
Ultrasound is most commonly performed for elevated liver
enzymes, and can show gallbladder sludge and distension, sugges-
tive of cholestasis [50]. 
Neurologic findings
Neurologic symptoms are not uncommon in COVID-19
patients, especially in severe stage of the disease [55-59]. Rarely,
they are the only presenting symptoms of COVID-19 [55]. As with
abdominal manifestations, the cause of neurologic impairment is
Review
Figure 6. Axial unenhanced CT image obtained in a 68-year-old
male COVID-19 patient shows extensive fibrosis and traction
bronchiectasis, involving the entire lung parenchyma.
Figure 7. Axial CT image obtained in a 60-year-old male COVID-
19 patient shows subpleural lines (arrow) in the lower right lobe. 
Figure 8. Axial unenhanced CT image obtained in a 40-year-old
male COVID-19 patient shows bilateral pleural effusion (arrows)
and pericardial effusion (arrowhead).
Figure 9. Axial unenhanced CT image obtained in a 69-year-old 
female COVID-19 patient shows multiple mediastinal lym-
phadenopathies (arrows).
ACE2 expression [55]. Main neurological findings are polyneu-
ropathy, encephalopathy, demyelinating lesions, brain microhem-
orrhage, and ischemic stroke (Figure 11) [55-59]. The latter can be
related to increased thrombosis rates in coronavirus infection [56].
Although imaging findings are not specific of COVID-19, CT and
MRI are strongly recommended for the evaluation of neurologic
involvement.
Conclusions
Although RT-PCR is the reference assessment for the diagnosis
of COVID-19 infection, imaging plays a crucial role for initial eval-
uation and follow-up of COVID-19 positive patients and to exclude
other disease conditions, which can be treated. Physicians should be
familiar with typical and atypical COVID-19 imaging findings.
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